Search the Community
Showing results for tags 'hypogonadism'.
Found 1 result
Biotech_Forecast posted an event in Biotech EventsANALYSIS OF 26 WEEK SAFETY DATA FROM STUDY QST-15-005 COMPLETED, NDA SUBMISSION REMAINS ON TRACK FOR FOURTH QUARTER 2016 EWING, NJ, September 22, 2016 -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced safety results from the dose-blinded, multiple-dose, concentration-controlled, 26-week phase 3 study of QuickShot® Testosterone (QST) administered subcutaneously once each week to adult males with hypogonadism. The study, QST-15-005, included a screening phase, a titration phase and a treatment phase for evaluation of safety and tolerability, including laboratory assessments, adverse events and injection site assessments.